Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02522208 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets
A Phase 1 study, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02522208 is a Phase 1 study that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT02522208, a Phase 1 study, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.
Interventions
- DRUG BiDil XR
- DRUG BiDil Immediate Release (IR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02522208
The ClinicalTrials.gov registry entry for NCT02522208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BiDil XR is the first listed.
NCT02522208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02522208 about?
NCT02522208 is a clinical study titled "Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets". This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.
What is the current status of trial NCT02522208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02522208?
The interventions under investigation include: BiDil XR (DRUG), BiDil Immediate Release (IR) (DRUG).
Who is sponsoring clinical trial NCT02522208?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.